Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Pleads Guilty To Off-Label Evista Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will pay a $36 mil. fine for promoting the osteoporosis drug for reduction in breast cancer risk.

You may also be interested in...



Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke

Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.

Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke

Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.

Investigation Into Cephalon’s Actiq Winding Down

Connecticut Attorney General’s office will meet with Cephalon next month to discuss marketing of the pain medication.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS061429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel